Consumer medicine information

Fluorouracil Ebewe

Fluorouracil

BRAND INFORMATION

Brand name

Fluorouracil Ebewe

Active ingredient

Fluorouracil

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Fluorouracil Ebewe.

What is in this leaflet

This leaflet answers some common questions about Fluorouracil Ebewe Injection. It does not contain all the available information.

It does not take the place of talking to your doctor and pharmacist.

All medicines have risks and benefits. Your doctor has weighed the risks of you being given Fluorouracil Ebewe Injection against the benefits they expect it will have for you.

If you have any concerns about being given this medicine, ask your doctor or pharmacist.

Keep this leaflet. You may need to read it again.

What Fluorouracil Ebewe is used for

This medicine is used to treat some types of cancer.

This medicine belongs to a group of medicines called antineoplastic or cytotoxic medicines. You may also hear of these being called chemotherapy medicines.

It works by killing cancer cells and stopping cancer cells from growing and multiplying. It may be used alone or in combination with other medicines to treat cancer.

Ask your doctor if you have any questions about why this medicine has been prescribed for you. Your doctor may have prescribed fluorouracil for another reason.

This medicine is not addictive.

It is available only with a doctor’s prescription.

Before you are given Fluorouracil Ebewe

When you must not be given it

You should not be given Fluorouracil Ebewe Injection if you have an allergy to Fluorouracil Ebewe.

Some of the symptoms of an allergic reaction may include shortness of breath, wheezing or difficulty breathing; swelling of the face, lips, tongue or other parts of the body; rash, itching or hives on the skin.

Tell your doctor if you have an infection or high temperature. Your doctor may decide to delay your treatment until the infection has gone. A mild illness, such as a cold, is not usually a reason to delay treatment.

Females: tell your doctor or pharmacist if you are pregnant or intend to become pregnant. Like most cytotoxic medicines, fluorouracil is not recommended for use during pregnancy. If there is any need to consider fluorouracil during your pregnancy, your doctor or pharmacist will discuss with you the benefits and risks of using it.

Males: tell your doctor or pharmacist if your partner intends to become pregnant while you are being given fluorouracil or shortly after you have stopped treatment with fluorouracil. Fluorouracil may cause birth defects if either the male or female is using it at the time of conception. It is recommended that you use some kind of birth control while you are using fluorouracil and for at least 12 weeks after you stop treatment. A barrier method of birth control, such as a condom, should be used while you are being given fluorouracil and for the first week of this 12 week period. Your doctor will discuss this with you.

Do not breast-feed if you are being treated with this medicine. It is not known whether fluorouracil passes into breast milk, and there is a possibility that your baby may be affected.

You must not be given this medicine if you have any of the following medical conditions:

  • problems with blood clotting
  • any blood disorder with a reduced number of red blood cells, white blood cells or platelets
  • lowered immunity due to diseases including HIV / AIDS or cancer
  • lowered immunity due to treatment with medicines such as corticosteroids, ciclosporin or other medicines used to treat cancer (including radiation therapy).
  • You have a poor diet or are debilitated

If you are not sure whether you should be given this medicine, talk to your doctor.

Before you are given it

Tell your doctor if you have allergies to any other medicines, foods, preservatives or dyes.

Tell your doctor if you have any medical conditions, especially the following:

  • heart disease
  • kidney disease
  • liver disease
  • any known enzyme deficiencies.

Tell your doctor if you have had previous radiation treatment or other cancer treatment.

If you have not told your doctor about any of the above, tell him/her before you are given fluorouracil.

Taking other medicines

Tell your doctor or pharmacist if you are taking any other medicines, including any that you get without a prescription from your pharmacy, supermarket or health food shop.

Some medicines and Fluorouracil Ebewe may interfere with each other. These include:

  • allopurinol (used to treat gout)
  • metronidazole (used to treat some types of infections)
  • cimetidine (used to treat stomach ulcers)
  • leucovorin (folinic acid) (used as an antidote to some cancer therapy)
  • levamisole (used to treat a type of colon cancer)
  • methotrexate and other medicines used to treat cancer).
  • phenytoin (used to treat epilepsy)

These medicines may be affected by Fluorouracil Ebewe, or may affect how well it works. You may need different amounts of your medicine, or you may need to take different medicines.

Your doctor and pharmacist may have more information on medicines to be careful with or avoid while being this medicine.

How Fluorouracil Ebewe is given

How much is given

Your doctor will decide what dose you will receive. This depends on your medical condition and other factors, such as your weight and height. Blood cell numbers, and renal and liver function.

Fluorouracil Ebewe Injection may be given alone or in combination with other drugs to treat cancer.

Several courses of Fluorouracil Ebewe therapy may be needed depending on your response to treatment.

Additional treatment may not be repeated until your blood cell numbers return to acceptable levels and any unwanted effects have been controlled.

Ask your doctor if you want to know more about the dose of Fluorouracil Ebewe you receive.

How it is given

Fluorouracil Ebewe can be given in three ways:

  • as an injection into a vein
  • as a continuous slow injection via a 'drip' into a vein
  • as a slow injection via a 'drip' into an artery.

Fluorouracil Ebewe must only be given by a doctor or nurse.

If you are given too much (overdose)

As Fluorouracil Ebewe Injection is given to you under the supervision of your doctor, it is very unlikely that you will receive an overdose. However, if you experience severe side effects tell your doctor immediately.

Symptoms of an overdose may include the side effects listed below in the 'Side Effects' section, but are usually of a more severe nature.

Ask your doctor or pharmacist if you have any concerns.

Please contact the Poisons Information Centre in Australia on 131 126 or in New Zealand on 0800 764 766 for advice on overdose management.

While you are being given Fluorouracil Ebewe

Things you must do

If you are about to be started on any new medicine, tell your doctor, dentist or pharmacist that you are being given Fluorouracil Ebewe.

Tell any other doctors, dentists and pharmacists who are treating you that you are being given this medicine.

If you become pregnant while you are being given Fluorouracil Ebewe tell your doctor immediately.

Keep all of your doctor’s appointments so your progress can be checked. Your doctor may want to do blood and other tests from time to time to check on your progress and detect any unwanted side effects.

Keep follow up appointments with your doctor. It is important to have your follow-up doses of fluorouracil at the appropriate times to get the best effects from your treatments.

Fluorouracil Ebewe can lower the number of white blood cells and platelets in your blood. This means that you have an increased chance of getting an infection or bleeding. The following precautions should be taken to reduce your risk of infection or bleeding:

  • Avoid people who have infections. Check with your doctor immediately if you think you may be getting an infection, or if you get a fever, chills, cough, hoarse throat, lower back or side pain or find it painful or difficult to urinate.
  • Be careful when using a toothbrush, toothpick or dental floss. Your doctor, dentist, nurse or pharmacist may recommend other ways to clean your teeth and gums. Check with your doctor before having any dental work.
  • Be careful not to cut yourself when you are using sharp objects such as a razor or nail cutters.
  • Avoid contact sports or other situations where you may bruise or get injured.

Your body breaks down fluorouracil and uses it to fight cancer. The breakdown products may be excreted in body fluids and waste, including blood, urine, faeces, vomitus and semen.

In general, precautions to protect other people should be taken while you are receiving chemotherapy and for one week after the treatment period by:

  • Flush the toilet twice to dispose of any body fluids and waste.
  • Wear gloves to clean any spill of body fluid or waste. Use paper towels or old rags, a strong solution of non-bleaching detergent and large amounts of water to mop up the spill. Discard the towels or rags into a separate waste bag and dispose of the fluids in the toilet.
  • Wash linen or clothing that is heavily contaminated by body fluids or waste separately from other items. Use a strong solution of non-bleaching detergent and large amounts of water.
  • Place soiled disposable nappies and other pads in a plastic bag, seal the bag and dispose into the garbage.
  • For sexual intercourse, use a barrier method such as a condom.

Things to be careful of

Be careful driving or operating machinery until you know how Fluorouracil Ebewe Injection affects you. This medicine may cause dizziness or confusion in some people. If you have any of these symptoms, do not drive, operate machinery, or do anything else that could be dangerous.

Be careful when drinking alcohol while you are taking this medicine. If you drink alcohol, dizziness or confusion may be worse.

Side effects

Tell your doctor or nurse as soon as possible if you do not feel well while you are being treated with Fluorouracil Ebewe.

Like other medicines that treat cancer, Fluorouracil Ebewe may have unwanted side effects, some of which may be serious. You may need medical treatment if you get some of the side effects.

If you are over 70 years of age, you may have an increased chance of getting side effects.

Tell your doctor, nurse or pharmacist if you notice any of the following and they worry you:

  • nausea
  • vomiting
  • diarrhoea
  • loss of appetite
  • hair loss
  • skin rash
  • change in skin or nail appearance
  • euphoria
  • headache
  • dizziness.

The above list includes side effects that are usually mild or short lived.

Tell your doctor immediately if you notice any of the following:

  • sore mouth, mouth ulcers
  • unsteady walking
  • changes in vision
  • jerky eye movements, excess tears, or uncomfortable sensitivity to light
  • tingling of the hands and feet followed by pain, redness and swelling
  • slurred speech
  • disorientation or confusion
  • an increased sensitivity of the skin to sunlight. (such as redness, itching, swelling, blistering) which may occur more quickly than normal. You should avoid being in the sunlight for too long
  • you should avoid being in the sunlight for too long
  • swelling, redness, or pain near the injection site.

The above list includes serious side effects, which may require medical attention.

If any of the following happen, tell your doctor or nurse immediately, or go to Accident and Emergency at your nearest hospital:

  • chest pain
  • loss of fingernails or toenails
  • irregular and/or rapid heart beat
  • signs of an infection (e.g. fever, chills, sore throat, cough)
  • unusual bleeding or bruising (such as bloody or black stools, blood in urine)
  • severe abdominal pain
  • severe mouth ulceration
  • difficulty swallowing
  • any signs of an allergic reaction such shortness of breath, wheezing or difficulty breathing; swelling of the face, lips, tongue or other parts of the body; rash, itching or hives on the skin.

The above list includes very serious side effects. You may need urgent medical attention.

Tell your doctor, nurse or pharmacist if you notice anything that is making you feel unwell.

Other side effects not listed above may occur in some people. Some of these side effects can only be found when your doctor does tests from time to time to check your progress.

The benefits and side effects of fluorouracil may take some time to occur. Therefore, even after you have finished receiving your fluorouracil treatment you should tell your doctor immediately if you notice any of the side effects listed in this section.

After using Fluorouracil Ebewe injection

Storage

Fluorouracil Injection will be stored in the pharmacy or on the ward. It must be protected from light and kept in a cool dry place where the temperature stays below 25°C. It should not be refrigerated or frozen.

Product description

What it looks like

Fluorouracil Ebewe Injection is a clear colourless solution in a glass vial.

Fluorouracil Ebewe comes in the following strengths:

  • Fluorouracil Ebewe injection 500 mg of fluorouracil in a 10 mL vial:
  • Fluorouracil Ebewe injection 1000 mg of fluorouracil in a 20 mL vial
  • Fluorouracil Ebewe injection 2500 mg of fluorouracil in a 50 mL vial
  • Fluorouracil Ebewe injection 5000 mg of fluorouracil in a 100 mL vial.

Not all presentations are marketed

Ingredients

Fluorouracil Ebewe contains fluorouracil as the active ingredient. It also contains:

  • Sodium hydroxide
  • Water for injections

Fluorouracil Ebewe Injection does not contain gluten, lactose, sucrose, tartrazine or any other azo dyes.

Vial stopper is not made with natural rubber latex.

Supplier

Sandoz Pty Ltd
ABN 60 075 449 553
54 Waterloo Road,
Macquarie Park,
NSW 2113, AUSTRALIA
Tel: 1800 726 369

This leaflet was prepared in December 2020.

Australian Registration Numbers

500 mg in 10 mLAUST R 98544

1000 mg in 20 mL AUST R 98545

2500 mg in 50 mL AUST R 166738

5000 mg in 100 mL AUST R 166741

Published by MIMS February 2021

BRAND INFORMATION

Brand name

Fluorouracil Ebewe

Active ingredient

Fluorouracil

Schedule

S4

 

1 Name of Medicine

Fluorouracil.

2 Qualitative and Quantitative Composition

Fluorouracil Ebewe contains 50 mg/mL of fluorouracil.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Solution for injection.

4 Clinical Particulars

4.1 Therapeutic Indications

Fluorouracil Ebewe is indicated alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas.
Fluorouracil should only be used when other proven measures have failed or are considered impractical.

4.2 Dose and Method of Administration

Dosage.

The dosage being based on the patient's actual weight. Ideal weight is used only if the patient is obese or if there has been a spurious weight gain due to oedema, ascites or other forms of abnormal fluid retention. Prior to treatment, each patient is to be carefully evaluated in order to estimate the optimum initial dosage of fluorouracil.
The total daily dose of fluorouracil should not exceed 1 g.
The following regimens have been recommended for use of fluorouracil as a single agent in adults:

Intravenous infusion.

15 mg/kg bodyweight (to a maximum of 1 g) daily diluted in 300 to 500 mL of glucose 5% given over a period of four hours. Infusions may be continued daily until the first gastrointestinal side effects occur, i.e. stomatitis, diarrhoea, leucopenia, thrombocytopenia; treatment should then be discontinued. After the side effects have subsided and the WBC count has risen to 3,000 to 4,000/mm3 or the platelet count to 80,000 to 100,000/mm3, the patient may then be placed on a maintenance therapy program.

Intravenous injection.

12 mg/kg bodyweight daily for three consecutive days.
If toxic effects do not appear, the patient may then be given 6 mg/kg may be given intravenously on the 5th, 7th and 9th days. If there are still no signs of toxicity, the patients may be placed on maintenance therapy, otherwise, regression of toxic side effects must be awaited before continuing therapy.

Maintenance therapy.

5 to 10 mg/kg bodyweight by intravenous injection once a week. Toxic symptoms seldom occur during maintenance therapy. If, however, they do appear, therapy must be discontinued until the symptoms regress, otherwise regression of toxic side effects must be awaited before continuing therapy.

Dose adjustments.

The initial recommended doses should be reduced by one-third to a half if any of the following conditions are present:
poor nutritional state;
after major surgery (within previous 30 days);
inadequate bone marrow function (white blood cell count < 5,000/mm3, platelet count < 100,000/mm3);
impaired hepatic and/or renal function.

Method of administration.

To reduce microbiological hazard, use as soon as practicable after reconstitution/ preparation.
If storage is necessary, hold at 2°C to 8°C for not more than 24 hours after preparation. Administration should be completed within 24 hours of preparation of the infusion and any residue discarded according to the guidelines for the disposal of cytotoxic drugs (see Section 6.6 Special Precautions for Disposal, Spills and disposal).
Fluorouracil Ebewe may be administered by intravenous infusion or intravenous injection.
Fluorouracil Ebewe may be used in combination with other cytostatic agents or with radiotherapy; in such cases, doses should be reduced accordingly. Fluorouracil Ebewe may also be administered as a 24 hour intra-arterial continuous drip infusion (5-7 mg/kg bodyweight daily).

Compatibilities.

Fluorouracil Ebewe is compatible with the following infusion media: 0.9% sodium chloride, 5% glucose, 0.9% sodium chloride with 5% glucose.
Fluorouracil Ebewe can be used in combination with other antitumour agents, but it is not recommended that it be mixed with these drugs in the same container.

4.3 Contraindications

Fluorouracil is contraindicated in patients:
who have any known hypersensitivity to fluorouracil or its excipients;
who are debilitated;
who are suffering a poor nutritional state;
who are suffering from bone marrow depression following radiotherapy or therapy with other antineoplastic agents (leucocyte count less than 5,000/mm3, platelet count less than 100,000/mm3);
who are suffering from a potentially serious infection;
who are pregnant; and
with known complete dihydropyrimidine dehydrogenase (DPD) deficiency (see Section 4.4 Special Warnings and Precautions for Use).
Fluorouracil must not be taken within 4 weeks of treatment with brivudine, sorivudine or their chemically related analogues. Brivudine, sorivudine and their analogues are potent inhibitors of the enzyme dihydropyrimidine dehydrogenase (DPD), which degrades fluorouracil (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions).

4.4 Special Warnings and Precautions for Use

Fluorouracil should be administered only by or under strict supervision of a qualified physician experienced in therapy with potent metabolites. Because of the possibility of severe toxic reactions, all patients should be hospitalized, at least during the initial course of therapy.
Fluorouracil should not be re-administered after a documented cardiovascular reaction (arrhythmia, angina, ST segment changes) as there is a risk of sudden death.

Toxicity.

Fluorouracil has a narrow margin of safety and is a highly toxic drug. The most pronounced and dose-limiting toxic effects of fluorouracil are on the normal, rapidly proliferating tissues of the bone marrow and the lining of the gastrointestinal tract. Fluorouracil therapy should be discontinued promptly whenever one of the following signs of toxicity appears: leucopenia, thrombocytopenia, stomatitis, oesophagopharyngitis, intractable vomiting, diarrhoea, melaena, haemorrhage, oral ulceration, evidence of gastrointestinal ulceration or bleeding.
Any form of therapy that adds to the stress of the patient, interferes with nutritional uptake or depresses bone marrow function will increase the toxicity of fluorouracil.
The ratio between effective and toxic dose is small and therapeutic response is unlikely without some degree of toxicity. Care must be taken, therefore, in the selection of patients and adjustment of dosage.

Myelosuppression.

Cytotoxic agents, including fluorouracil, may produce myelosuppression (including, but not limited to leucopenia, granulocytopenia, pancytopenia, and thrombocytopenia). Leucopenia and thrombocytopenia commonly follow treatment with fluorouracil.
The initial dose should be reduced, or treatment should not be started in the presence of diminished leucocytes and/or platelets (see Section 4.3 Contraindications; Section 4.2 Dose and Method of Administration).
Leucopenia occurs after nearly every treatment period with an effective dose. The nadir for white blood cell count usually occurs from the 9th to the 14th day after initiation of therapy, but may occur as late as the 25th day. The count usually returns to normal by the 30th day. Thrombocytopenia may also occur, with the lowest platelet counts occurring from the 7th to the 17th day of therapy.
Daily monitoring of platelet and white blood cell counts is recommended. Treatment with fluorouracil should be discontinued if the leucocyte count falls rapidly or if it falls below 3,500/mm3, or if there is a fall in the platelet count below 100,000/mm3. If the leucocyte count falls below 2,000/mm3, the patient should be placed in an isolation unit and given an appropriate preventative treatment for systemic infection.
Clinical consequences of severe myelosuppression include infections. Viral, bacterial, fungal and/or parasitic infections, either localised or systemic, may be associated with the use of fluorouracil alone or in combination with other immunosuppressive agents. These infections may be mild, but can be severe and at times fatal.

Cardiotoxicity.

Fluorouracil administration has been associated with myocardial ischaemia, cardiomyopathy and, very rarely, sudden death. Angina, tachycardia, breathlessness, arrhythmia, ECG abnormalities, myocardial infarction and stress cardiomyopathy (Takotsubo syndrome) have been reported after administration of fluorouracil. Attention should therefore be paid to patients who experience chest pain during treatment, and patients with a history of heart disease. There is an increased risk of death associated with re-administration of fluorouracil in patients with a documented cardiovascular reaction (see Section 4.8 Adverse Effects (Undesirable Effects)).

Combination chemotherapy/ radiotherapy.

May depress bone marrow function and increase the toxicity of fluorouracil. Extreme caution is necessary when administering fluorouracil to patients who have had high dose pelvic irradiation or have been previously treated with alkylating agents, and in those who have a widespread involvement of bone marrow by metastatic tumours. Radiation therapy on the bone marrow, especially to the area of the chest and mediastinum, may potentiate the bone marrow effects of fluorouracil. Fluorouracil treatment may potentiate necrosis caused by radiation. Concomitant use of other chemotherapeutic agents may depress bone marrow function and increase the toxicity of fluorouracil.

Dihydropyrimidine dehydrogenase deficiency.

Rarely, severe toxicity (e.g. stomatitis, diarrhoea, neutropenia, and neurotoxicity) associated with fluorouracil has been attributed to deficiency of dihydropyrimidine dehydrogenase (DPD) activity. DPD-deficiency related toxicity usually occurs during the first cycle of treatment or after dose increase. Fatal outcome has been reported in some cases. Absence of this catabolic enzyme appears to result in prolonged clearance of fluorouracil. Special attention should be given to DPD status before therapy through laboratory testing for the detection of total or partial DPD-deficiency, or when evaluating patients experiencing fluorouracil-related toxicities.
Patients with complete DPD deficiency are at high risk of life-threatening or fatal toxicity and must not be treated with fluorouracil injection (see Section 4.3 Contraindications). Patients with partial DPD deficiency are at increased risk of severe and potentially life-threatening toxicity. A reduced starting dose should be considered to limit this toxicity. DPD deficiency should be considered as a parameter to be taken into account in conjunction with other routine measures for dose reduction. Initial dose reduction may impact the efficacy of treatment. Consideration should be given to applicable clinical guidelines.

Gastrointestinal effects.

Loss of appetite, nausea and vomiting are common adverse effects, which generally occur during the first week of therapy. These adverse effects may be treated symptomatically and can often be alleviated by antiemetics. Stomatitis is usually an early sign of impending severe toxicity which may become evident as early as the fourth day, but more commonly appears after 5-8 days of therapy. Symptoms include soreness, erythema or ulceration of the oral cavity or dysphagia. Other reported gastrointestinal symptoms are diarrhoea, proctitis and oesophagitis, therefore, the dose may require adjustment or therapy may need to be discontinued. Diarrhoea is usually mild and occurs later in treatment. Severe diarrhoea may also be accompanied by dehydration and melaena. Gastrointestinal side effects may be exacerbated if fluorouracil is given with folinic acid.

Immunosuppressant effects/increased susceptibility to infections.

Administration of live or live attenuated vaccines in patients immunocompromised by chemotherapeutic agents including fluorouracil, may result in serious or fatal infections. Vaccination with a live vaccine should be avoided in patients receiving fluorouracil. Killed or inactivated vaccines may be administered; however, the response to such vaccines may be diminished.

Photosensitivity reactions.

Some patients may experience photosensitivity reactions following administration of fluorouracil, it is recommended that patients are warned to avoid prolonged exposure to sunlight (see Section 4.8 Adverse Effects (Undesirable Effects)).

Combination with phenytoin.

Patients taking phenytoin concomitantly with fluorouracil should undergo regular testing because of the possibility of an elevated plasma level of phenytoin (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions).

Hand-foot syndrome.

The administration of fluorouracil has been associated with the occurrence of palmar-plantar erythrodysesthesia syndrome, also known as hand-foot syndrome. Continuous-infusion fluorouracil may increase the incidence and severity of palmar-plantar erythrodysesthesia. This syndrome has been characterised as a tingling sensation of hands and feet, which may progress over the next few days to pain when holding objects or walking. The palms and soles become symmetrically swollen and erythematous with tenderness of the distal phalanges, possibly accompanied by desquamation. Interruption of therapy is followed by gradual resolution over 5 to 7 days. Supplementation of chemotherapy with oral pyridoxine has been reported to prevent or resolve such symptoms.

Multifocal inflammatory leucoencephalopathy (MILE).

Combination therapy with 5-fluorouracil and levamisole has been associated with multifocal inflammatory leucoencephalopathy (MILE). Symptoms may include memory loss, confusion, paraesthesia, lethargy, muscle weakness, speech disturbances, coma and seizures. The cerebrospinal fluid may show mild pleocytosis, and computed tomography and magnetic resonance scans may show lesions in the white matter suggestive of demyelination. If this syndrome occurs, treatment should be discontinued immediately. The condition is at least partially reversible if 5-fluorouracil and levamisole are discontinued and corticosteroids given.

Wernicke's encephalopathy.

Fluorouracil showed some evidence of interference with the metabolism of thiamine (vitamin B1). Studies performed in patients treated with fluorouracil showed a reduction of thiamine levels following fluorouracil administration; the thiamine level reduction potentially induced by fluorouracil can facilitate the onset of Wernicke's encephalopathy. Adequate monitoring of thiamine levels, and thiamine supplementation may be required.

Tumour lysis syndrome.

Cases of tumour lysis syndrome associated with fluorouracil treatment have been reported from post-marketing sources. Patients at increased risk of tumour lysis syndrome (e.g. with renal impairment, hyperuricemia, high tumour burden, rapid progression) should be closely monitored. Preventive measures (e.g. hydration, correction of high uric acid levels) should be considered.

Compatibilities.

See Section 4.2 Dose and Method of Administration, Compatibilities.

Use in hepatic impairment.

Fluorouracil should be used with caution in patients with reduced liver function or jaundice.

Use in renal impairment.

Fluorouracil should be used with caution in patients with reduced renal function or heart disease.

Use in the elderly.

Fluorouracil should be used with caution in elderly patients. An age of 70 years or older and the female gender are statistically significant risk factors for severe toxicity from fluorouracil based chemotherapy. These effects may be additive in older women. While advanced age does not contraindicate the use of this type of chemotherapy, close monitoring for multiple organ toxicities and vigorous supportive care of those with toxicity are required.

Paediatric use.

No data available.

Effects on laboratory tests.

Fluorouracil could interfere with diagnostic tests of thyroid function by causing rises in total thyroxine and liothyronine due to increased globulin binding. Plasma albumin may be decreased because of drug-induced protein malabsorption.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Cytotoxic agents.

All myelosuppressive drugs (e.g. cytotoxic agents used in combination chemotherapy) can increase haematotoxicity of fluorouracil.

Folinic acid (leucovorin).

Enhances the DNA-directed toxicity of fluorouracil. This combination should be used with caution as the toxicity of fluorouracil, especially, GI and haematologic, may be increased. Careful monitoring should be observed and the dose of fluorouracil may be decreased based on current guidelines.

Allopurinol.

Allopurinol may decrease the degree of bone marrow depression produced by fluorouracil. Studies of this possibility have reported conflicting results.
Various agents have been reported to biochemically modulate the antitumour efficacy or toxicity of fluorouracil. Common medicines include methotrexate, metronidazole and folinic acid (leucovorin).

Metronidazole.

Metronidazole may enhance the toxicity of fluorouracil. The mechanism of interaction is presumed to be reduced clearance of fluorouracil by metronidazole. Concurrent administration should be avoided.

Levamisole.

Combination therapy with 5-fluorouracil and levamisole has been associated with multifocal inflammatory leukoencephalopathy (MILE). The use of levamisole and 5-fluorouracil is no longer recommended by NH and MRC 'Clinical Practice guidelines: The prevention, early detection and management of colorectal cancer'. This combination regimen has been superseded by fluorouracil and folinic acid (see Section 4.4 Special Warnings and Precautions for Use).

Cimetidine.

Pretreatment with cimetidine prior to intravenous fluorouracil increased the fluorouracil area under the concentration time curve (AUC) by 27%. The total body clearance was reduced by 28%. This may lead to increased plasma concentrations of fluorouracil. This effect is probably due to both inhibition of hepatic enzymes and reduction of hepatic blood flow. Caution should be taken if the patient receives fluorouracil and cimetidine concurrently.

Phenytoin.

Increased phenytoin plasma concentrations have been reported during concomitant use of phenytoin with capecitabine or its metabolite fluorouracil. Formal interaction studies between phenytoin and capecitabine have not been conducted, but the mechanism of interaction is presumed to be inhibition of CYP2C9 isoenzyme system by capecitabine. Serum levels of phenytoin sustained above the optimal range may produce encephalopathy or confusional states (delirium psychosis) or rarely irreversible cerebellar dysfunction. Therefore, patients taking phenytoin concomitantly with capecitabine or fluorouracil should be regularly monitored for increased phenytoin plasma levels, and the phenytoin dosage may need to be reduced (see Section 4.4 Special Warnings and Precautions for Use).

Brivudine and sorivudine.

Brivudine, sorivudine or their chemically related analogues irreversibly inhibit DPD, resulting in a significant increase in fluorouracil exposure. This may lead to increased fluoropyrimidine-related toxicities with potentially fatal outcome. Therefore, either a different antiviral therapy may be used or there should be an interval of at least 4 weeks between the administration of brivudine, sorivudine, or the analogues and the start of fluorouracil treatment (see Section 4.3 Contraindications). In the case of accidental administration of nucleoside analogues that inhibit DPD activity to patients treated with fluorouracil, effective measures should be taken to reduce fluorouracil toxicity. Immediate hospitalization is recommended.

Radiation therapy.

Radiation therapy on the bone marrow, especially to the area of the chest and mediastinum, may potentiate the bone marrow effects of fluorouracil.

Warfarin.

Elevated INR levels and occasional episodes of bleeding have been reported during concomitant use of warfarin and fluorouracil or its analogues. In these cases, fluorouracil has usually been administered as one component of an antineoplastic combination regimen. Adequate anticoagulant response to warfarin and other coumarin-derivative therapy should be monitored regularly in patients taking fluorouracil.

Thiamine (vitamin B1).

Fluorouracil treatment may interfere with the metabolism of thiamine (vitamin B1). Thiamine level reduction may facilitate the onset of Wernicke's encephalopathy (see Section 4.4 Special Warnings and Precautions for Use; Section 4.8 Adverse Effects (Undesirable Effects)).

Live or live-attenuated vaccines.

Administration of live or live-attenuated vaccines in patients immunocompromised by chemotherapeutic agents including fluorouracil, may result in serious or fatal infections (see Section 4.4 Special Warnings and Precautions for Use).

Laboratory values.

Fluorouracil treatment may interfere with some laboratory tests. Increases in total serum thyroxine concentration (due to increased binding to globulin) have been reported.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

Fluorouracil has not been adequately studied in animals to permit an evaluation of its effects on fertility and general reproductive performance. However, doses of 125 or 250 mg/kg, administered intraperitoneally, have been shown to induce chromosomal aberrations and changes in chromosomal organisation of spermatogonia in rats. Spermatogonial differentiation was also inhibited by fluorouracil, resulting in transient infertility. However, in studies with a strain of mouse which is sensitive to the induction of sperm head abnormalities after exposure to a range of chemical mutagens and carcinogens, fluorouracil did not produce any abnormalities at oral doses of up to 80 mg/kg/day. In female rats, fluorouracil, administered intraperitoneally at weekly doses of 25 or 50 mg/kg for three weeks during the pre-ovulatory phase of oogenesis, significantly reduced the incidence of fertile matings, delayed the development of pre- and post-implantation embryos, increased the incidence of pre-implantation lethality and induced chromosomal anomalies in these embryos. In a limited study in rabbits, a single 25 mg/kg dose of fluorouracil or 5 daily doses of 5 mg/kg had no effect on ovulation, appeared not to affect implantation and had only a limited effect in producing zygote destruction. Compounds such as fluorouracil, which interfere with DNA, RNA and protein synthesis, might be expected to have adverse effects on gametogenesis. In general, use of a contraceptive is recommended during cytotoxic therapy.
(Category D)
Fluorouracil may cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women, however, fetal defects and miscarriages have been reported. Fluorouracil administered parenterally has been shown to be teratogenic in mice, rats and hamsters, and embryolethal in monkeys. Fluorouracil is strictly contraindicated in pregnancy. Safety for use in pregnancy has not been established. Women of childbearing age should be advised to avoid pregnancy during fluorouracil therapy and to use a highly effective method of contraception during fluorouracil therapy and for at least 6 months after last dose. Fluorouracil should only be used in women of child bearing potential if the expected benefits outweigh the risks of therapy, and adequate contraception is used. If the patient becomes pregnant whilst receiving the drug, she should be advised of the potential hazards to the foetus. It is also recommended to advise the patient to seek genetic counselling prior to treatment with fluorouracil, if appropriate and available.
Men treated with fluorouracil should be advised not to father a child during and for at least 3 months following cessation of treatment and also ensure they use effective contraception measures.
 It is not known whether fluorouracil is excreted in breast milk. To avoid possible harmful effects in the infant, breastfeeding is not advised during fluorouracil therapy.

4.7 Effects on Ability to Drive and Use Machines

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 Adverse Effects (Undesirable Effects)

The ratio between effective and toxic dose is small and therapy with fluorouracil is usually accompanied by some degree of adverse effects. Adverse effects of fluorouracil mainly result from its effects on rapidly dividing cells of normal tissue and its effect on the gastrointestinal tract and haematopoietic systems (see Section 4.4 Special Warnings and Precautions for Use). Patients should be very carefully observed and dosage adjustment may have to be made. Deaths have been reported.

Gastrointestinal.

The most pronounced and dose limiting toxic effects of fluorouracil are on the normal, rapidly proliferating cells of the bone marrow and the lining of the gastrointestinal tract.
Nausea and vomiting occur and may be treated symptomatically. Other reported gastrointestinal symptoms are diarrhoea, stomatitis, proctitis, melaena, gastrointestinal haemorrhage, gastrointestinal ulcer and oesophagitis, therefore, the dose may require adjustment or therapy may need to be discontinued. Gastrointestinal side effects may be exacerbated if fluorouracil is given with folinic acid (leucovorin) (see Section 4.4 Special Warnings and Precautions for Use).

Hepatobiliary disorders.

Hepatocellular injury.

Metabolism and nutrition disorders.

Dehydration, decreased appetite, tumour lysis syndrome.

Immune system disorders.

Anaphylactic reaction, hypersensitivity.

Dermatological.

Alopeciaa may be seen in a substantial number of cases, but it is reversible. Nails disordersb, dermatitisc, cutaneous lupus erythematosus and hyperpigmentation of the nail beds and other body areasd have been reported. Skin rashes and fissures have been associated with fluorouracil therapy. Palmar-plantar erythrodysaesthesia syndromee, thrombophlebitis and asymptomatic hyperpigmentation over vascular channels have also been reported. Continuous-infusion fluorouracil may increase incidence and severity of palmar-plantar erythrodysaesthesia, photosensitivity reactions.

Neurotoxicityh.

Neurotoxicity may be evidenced by disorientation, confusion, euphoria, ataxia, dizziness, headache, muscular weakness, nystagmus, slurred speech, unsteadiness and acute cerebellar syndrome, Wernicke's encephalopathy and occasionally, oculomotor disturbances, have occurred in patients receiving fluorouracil. These symptoms may persist after therapy is discontinued.

Haematological.

Leucopenia, primarily granulocytopenia, commonly occurs. The nadir for white blood cell count usually occurs from the 9th to the 14th day after initiation of therapy, but may occur as late as the 25th day. The count usually returns to normal by the 30th day. Thrombocytopenia may also occur, with the lowest platelet counts occurring from the 7th to the 17th day of therapy.
Bone marrow failure and pancytopenia may also occur.

Cardiovascular.

There have been reports of chest pain, tachycardiaf, breathlessness, arrhythmiaf, and ECG changes (ST segment changes), angina pectorisf,g, myocardial ischaemiaf, myocardial infarctionf, cardiac shockf, cardiac failuref, myocarditisf, cardiomyopathyf, pericarditisf, stress cardiomyopathyf, thrombophlebitis and haemorrhage after administration of fluorouracil. There have been reports of sudden death in patients readministered fluorouracil after a documented cardiovascular reaction.

Ocular.

Systemic fluorouracil treatment has been associated with various types of ocular toxicity. Additionally, several other reports have been noted including excessive lacrimation, dacryostenosis, visual changes and photophobia.

Neurological.

Combination therapy with 5-fluorouracil and levamisole has been associated with leucoencephalopathyh and multifocal inflammatory leucoencephalopathy (MILE) (see Section 4.4 Special Warnings and Precautions for Use).

Infections and infestations.

Septic shock, sepsis, neutropenic sepsis, progressive multifocal leukoencephalopathy pneumonia, superinfection, urinary tract infection, catheter related infection, cellulitis, pharyngitis, and other infections.

Other.

Local injection site reaction. Fever has also been reported. Rarely, anaphylaxis or generalised allergic reactions have occurred in patients receiving fluorouracil. Pyrexia and chest pain.
a Reversible.
b Such as partial or complete detachment of nails.
c Manifests often as itchy maculopapular rash on the extremities.
d Skin hyperpigmentation also refers to asymptomatic hyperpigmentation over vascular channels.
e Observed in patients who received 5-fluorouracil and leucovorin bolus administration.
f Listed cardiac disorders associated with 5-fluorouracil, may lead to cardiac arrest.
g Observed in patients receiving high dose leucovorin and 5-fluorouracil bolus and continuous infusion.
h Symptoms may persist after therapy is discontinued.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

Signs and symptoms.

The possibility of overdosage with fluorouracil is unlikely in view of the mode of administration. High dosages or prolonged treatment with fluorouracil can result in life-threatening intoxication symptoms; the anticipated manifestations include nausea, vomiting, diarrhoea, gastrointestinal ulceration, haemorrhage and myelosuppression (including thrombocytopenia, leucopenia and granulocytopenia).

Treatment.

Uridine triacetate is a specific antidote for the treatment of 5-fluorouracil overdose or the treatment of severe early-onset toxicities. It should be administered within 96 hours after end of 5-fluorouracil infusion. In the event uridine triacetate is not available, treatment is symptomatic and supportive. Patients who have been exposed to an overdose of fluorouracil should be monitored haematologically for at least 4 weeks. Should abnormalities appear, appropriate therapy should be utilised.
For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Fluorouracil is an analogue of uracil, a component of ribonucleic acid. The drug is believed to function as an antimetabolite. Fluorouracil itself is inactive and is converted intracellularly to active metabolites. After conversion to the active deoxynucleotide, it interferes with the synthesis of DNA by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase. Fluorouracil may also interfere with RNA synthesis.

Clinical trials.

No data available.

5.2 Pharmacokinetic Properties

Absorption.

It is preferentially taken up by actively dividing tissues and tumours after conversion to its nucleotide.

Distribution.

After intravenous administration, fluorouracil is distributed throughout body tissues and fluids. The plasma half-life is 8 to 22 minutes and is dose dependent. Fluorouracil readily enters the cerebrospinal fluid (CSF).

Metabolism.

80% is mostly metabolised in the liver by the usual body mechanisms for uracil.

Excretion.

Fluorouracil disappears from the blood within four hours. About 20% is excreted unchanged in the urine.

5.3 Preclinical Safety Data

Genotoxicity.

Oncogenic transformation of fibroblasts from mouse embryo has been induced in vitro by fluorouracil, but the relationship between oncogenicity and mutagenicity is not clear. A positive effect was observed in the micronucleus test on bone marrow cells of the mouse, and fluorouracil at very high concentrations produced chromosomal breaks in hamster fibroblasts in vitro.

Carcinogenicity.

Long-term studies in animals to evaluate the carcinogenic potential of fluorouracil have not been concluded. However, there was no evidence of carcinogenicity in small groups of rats given fluorouracil orally at doses 0.01, 0.3, 1 or 3 mg per rat 5 days per week for 52 weeks, followed by a 6 month observation period. On the basis of the available data, no evaluation can be made of the carcinogenic risk of fluorouracil to humans.

6 Pharmaceutical Particulars

6.1 List of Excipients

Water for injections, sodium hydroxide.

6.2 Incompatibilities

Admixtures with acidic medicines or medicines that decompose in an alkaline environment should be avoided. See Section 4.2 Dose and Method of Administration, Compatibilities.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 25°C. Do not refrigerate. Do not freeze. Protect from light.

6.5 Nature and Contents of Container

Fluorouracil Ebewe 500 mg/10 mL injection solution vial - glass vial: Pack of 1 or 5 vials.
Fluorouracil Ebewe 1000 mg/20 mL injection solution vial - glass vial: Pack of 1 vial.
Fluorouracil Ebewe 2500 mg/50 mL injection solution vial - glass vial: Pack of 1 vial.
Fluorouracil Ebewe 5000 mg/100 mL injection solution vial - glass vial: Pack of 1 vial.
Not all strengths or presentations may be marketed in Australia.
Vial stopper is not made with natural rubber latex.

6.6 Special Precautions for Disposal

As with all antineoplastic agents, trained personnel should prepare Fluorouracil Ebewe. This should be performed in a designated area (preferably a cytotoxic laminar flow cabinet) with table surfaces protected with disposable plastic-backed absorbent paper, should be designated for the handling of the drug. Protective gown, mask, gloves and appropriate eye protection should be worn when handling fluorouracil. Where solution accidentally contacts skin or mucosa, the affected area should be immediately washed thoroughly with soap and water and a physician contacted. It is recommended that pregnant personnel not handle cytotoxic agents such as fluorouracil.
Luer-Lok fitting syringes are recommended. Large bore needles are recommended to minimise pressure and possible formation of aerosols. Aerosols may also be reduced by using a venting needle during preparation.
Fluorouracil Ebewe contains no antimicrobial agent. The product is for single use in one patient only. Discard any residue.
Items used to prepare Fluorouracil Ebewe, or articles associated with body waste should be disposed of by placing in a double sealed polythene bag and incinerated at 1100°C.

Spills and disposal.

If spill occurs, restrict access to the affected area. Wear two pairs of latex rubber gloves, a suitable mask, a protective gown and safety glasses. Limit the spread of the spill by covering with a suitable material such as absorbent towels or adsorbent granules. Spills may also be treated with sodium hypochlorite 5%. Collect the absorbent/ adsorbent and other debris from the spill and place in a leakproof plastic container and label accordingly. Cytotoxic waste should be regarded as toxic and hazardous and clearly labeled 'Cytotoxic waste for incineration at 1100°C'. Waste material should be incinerated at 1100°C for at least one second. Clean the remaining spill area with copious amounts of water.
If a precipitate has formed as a result of exposure to low temperatures, redissolve by heating to 60°C accompanied by vigorous shaking. Allow to cool to body temperature prior to use.
In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical Properties

Fluorouracil is a white to almost white, practically odourless, crystalline powder. It is sparingly soluble in water, slightly soluble in alcohol and practically insoluble in chloroform and ether. The pH of the fluorouracil injection solution is approximately 8.9.

Chemical structure.


Chemical name: 5-fluoro-1H,3H-pyrimidine-2,4-dione.
Molecular formula: C4H3FN2O2.
Molecular weight: 130.1.

CAS number.

51-21-8.

7 Medicine Schedule (Poisons Standard)

S4 - Prescription Only Medicine.

Summary Table of Changes